Targeting the cancer microenvironment

The recognition of bacterial infections or foreign substances is mediated and controlled by the human immune system. This innate and adaptive immune system comprises the most important metabolic and cellulare processes to fight against infections and other diseases. Paradoxically, this immune system is also involved in the development of systemic diseases and cancer. Therefore it is of utmost importance to further understand fundamental biochemical processes involved in the cellular reactions of the immune system which can lead directly to novel therapies against systemic diseases and cancer.

The enormeous complexity of the immune system comprises different cell types. Two types, M1- and M2-type macrophages are involved in inflammatory defense mechanisms (M1) but also healing processes (M2). These M2-type macrophages are also known to associate with cancer cells and supporting their growth (Tumor-associated macrophages, TAM´s). The mechanism by which these cell types can differentiate into each other is called the polarization process.

M2 polarization can be targeted by a novel biochemical checkpoint

In a new study published in Cell Reports the research teams of the system biologist and biochemist Wolfram Weckwerth and the immunologist Thomas Weichhart have found a novel biochemical switch involved in the polarization and proliferation of M2 macrophages. This biochemical checkpoint branches from the glycolytic pathway - the major pathway in human metabolism for glucose breakdown - to provide molecular units for rapid cell proliferation and differentiation. If this pathway is inhibited by specific substances the M2 polarization and proliferation is downregulated. This has direct consequences for the understanding of TAM's and the treatment of cancer. „Our hypothesis is that if we inhibit the growth of M2-type macrophages in the microenvironment of cancer cells we could revoke the supportive effect for cancer growth. This biochemical checkpoint which we found in these M2-type macrophages is exactly the point for targeting their growth inhibition," says Wolfram Weckwerth.

The two labs of Thomas Weichhart and Wolfram Weckwerth are now intensively working to study this mechanism in more detail and to develop potential strategies for cancer cell treatment. Central for this project is the Vienna Metabolomics Center which enables the thorough study of these complex metabolic processes of the human immune system and cancer metabolism by combining metabolite profiling and data-driven computational modelling. The Vienna Metabolomics Center was also recently involved in a study for cancer treatment by specific combinations of fasting and drug administration leading to reduced tumor growth.

Jayne Louise Wilson, Thomas Nägele, Monika Linke, Florian Deme, Stephanie D Fritsch, Hannah Katharina Mayr, Zhengnan Cai, Karl Katholnig, Xiaoliang Sun, Lena Fragner, Anne Miller, Arvand Haschemi, Alexandra Popa, Andreas Bergthaler, Markus Hengstschläger, Thomas Weichhart, Wolfram Weckwerth.
Inverse Data-Driven Modeling and MultiomicsAnalysis Reveals Phgdh as a Metabolic Checkpointof Macrophage Polarization and Proliferation.
Cell Reports 30, 1542–1552, February 4, 2020. doi: 10.1016/j.celrep.2020.01.011.

Most Popular Now

COVID-19 vaccine protection wanes after three mont…

The protection offered by the Oxford-Astra Zeneca COVID-19 vaccine declines after three months of receiving two doses, a study says. The findings - drawn from datasets...

New study adds more evidence for Omicron immune ev…

A new study from Columbia researchers, in collaboration with scientists at the University of Hong Kong, adds more evidence that the omicron variant can evade the immune p...

European Commission grants conditional marketing a…

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announce...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Vaxzevria significantly boosted antibody levels ag…

AstraZeneca's Vaxzevria (ChAdOx1-S [Recombinant]) significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.1.529) following a third dose boo...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...